文献速递外周动脉疾病

随机对照试验衍生模型对慢性肢体威胁性缺血干预后结局的验证

Validation of randomized controlled trial-derived models for the prediction of postintervention outcomes in chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2019-09-26

本研究在Athero-Express注册研究和荷兰两项CLTI随机对照试验(JUVENTAS、PADI)数据中验证BASIL、FINNVASC和PREVENT III模型的预测效能。主要结局为无截肢生存(AFS),次要结局为12个月全因死亡和截肢。结果显示各模型预测死亡和截肢的效能为差至中等,BASIL模型预测AFS表现最佳。

要点

  • BASIL与PREVENT III模型对JUVENTAS队列干预后死亡具有预测价值
  • FINNVASC模型对PADI人群12个月截肢风险预测效能最高
  • 各模型总体预测效能为差至中等,尚需改进方可用于临床决策

核心结论

  • 各模型预测死亡与截肢的效能总体为差至中等。
  • BASIL模型预测AFS表现最佳,建议用于辅助CLTI临床决策。
  • 任何模型若要在临床实践中具有实际附加价值,均需改进效能。

研究设计与样本

  • 验证研究,在Athero-Express注册研究及JUVENTAS、PADI两项荷兰CLTI随机对照试验数据中验证BASIL、FINNVASC和PREVENT III模型。
  • 采用受试者工作特征(ROC)曲线分析计算预测效能。

主要发现

  • BASIL和PREVENT III模型对JUVENTAS队列干预后死亡具有预测价值,AUC分别为81%和70%。
  • 各模型在各人群中预测AFS的AUC为0.60-0.71,BASIL模型在JUVENTAS人群中最高为71%。
  • FINNVASC模型对PADI人群12个月截肢风险预测价值最高,AUC为78%。

临床怎么用

  • 可考虑使用BASIL模型辅助CLTI临床决策。
  • 现有模型预测效能有限,不宜单独作为决策依据。

局限性

  • 各模型预测效能总体仅为差至中等,需进一步改进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic limb-threatening ischemia (CLTI) represents the most severe form of peripheral artery disease and has a large impact on quality of life, morbidity, and mortality. Interventions are aimed at improving tissue perfusion and averting amputation and secondary cardiovascular complications with an optimal risk-benefit ratio. Several prediction models regarding postprocedural outcomes in CLTI patients have been developed on the basis of randomized controlled trials to improve clinical decision-making. We aimed to determine model performance in predicting clinical outcomes in selected CLTI cohorts. METHODS: This study validated the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL), Finland National Vascular registry (FINNVASC), and Prevention of Infrainguinal Vein Graft Failure (PREVENT III) models in data sets from a peripheral artery disease registry study (Athero-Express) and two randomized controlled trials of CLTI in The Netherlands, Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) and Percutaneous Transluminal Angioplasty and Drug-eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI). Receiver operating characteristic (ROC) curve analysis was used to calculate their predictive capacity. The primary outcome was amputation-free survival (AFS); secondary outcomes were all-cause mortality and amputation at 12 months after intervention. RESULTS: The BASIL and PREVENT III models showed predictive values regarding postintervention mortality in the JUVENTAS cohort with an area under the ROC curve (AUC) of 81% and 70%, respectively. Prediction of AFS was poor to fair (AUC, 0.60-0.71) for all models in each population, with the highest predictive value of 71% for the BASIL model in the JUVENTAS population. The FINNVASC model showed the highest predictive value regarding amputation risk in the PADI population with AUC of 78% at 12 months. CONCLUSIONS: In general, all models performed poor to fair in predicting mortality and amputation. Because the BASIL model performed best in predicting AFS, we propose use of the BASIL model to aid in the clinical decision-making process in CLTI. However, improvements in performance have to be made for any of these models to be of real additional value in clinical practice.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wijnand JGJ, van Koeverden ID, Teraa M, et al. Validation of randomized controlled trial-derived models for the prediction of postintervention outcomes in chronic limb-threatening ischemia. J Vasc Surg. 2019. PMID: 31564582. doi:10.1016/j.jvs.2019.06.195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。